Consensus CONMED Corporation

Equities

CNMD

US2074101013

Market Closed - Nyse Other stock markets 04:00:02 2024-04-23 pm EDT			5-day change	1st Jan Change
71.31 ^USD	-1.79%		-1.99%	-34.88%

Apr. 08	CONMED Corporation Announces Not Stand for Re-Election of Jerome Lande as Director	CI
Feb. 01	Sector Update: Health Care Stocks Rise in Late Afternoon	MT

Evolution of the average Target Price on CONMED Corporation

Price target over the last 5 years

History of analyst recommendation changes

d38fcf0102d930334.cBMRulRFa2yf_4b3PiAgTuXE2-KWCHwN-6TXpwgHimk.P1wi0QYTAjvnzMqARBN_BNX2tq3-RyVevJeIlkQ03w4nKn_SZHxaCNmQ9Q~872548549853e04fca6c6a6a8cb281e7

Analyst Recommendations on CONMED Corporation

Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	Feb. 01	MT
JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	Feb. 01	MT
Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	23-10-27	MT
Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	23-10-26	MT
Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	23-07-27	MT
Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	23-07-27	MT
Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	23-06-05	MT
CL King Starts CONMED at Buy With $140 Price Target	23-05-22	MT
Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	23-04-27	MT
Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	23-04-27	MT
Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	23-04-27	MT
Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	23-04-27	MT
CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving	23-03-27	MT
ANALYST RECOMMENDATIONS : Caterpillar, Conmed, Corning, Model N, United Rentals...	23-03-27
Needham Raises Price Target on CONMED to $122 From $106, Maintains Buy Rating	23-02-03	MT
Piper Sandler Adjusts CONMED's Price Target to $118 From $108, Maintains Overweight Rating	23-02-03	MT
Needham Cuts Price Target on CONMED to $90 From $123, Citing Currency Headwind, Inflation, Peer Multiple Contraction; Buy Rating Kept	22-10-14	MT
Jefferies Starts CONMED at Hold With $85 Price Target	22-10-12	MT
Needham Trims CONMED's Price Target to $123 From $127 on Near-Term Earnings Dilution From Biorez Deal; Buy Rating Kept	22-08-02	MT
Piper Sandler Adjusts CONMED's Price Target to $118 From $160, Reiterates Overweight Rating	22-07-28	MT
Needham Adjusts CONMED's Price Target to $127 From $155, Noting Currency Headwinds, Keeps Buy Rating Amid Accelerating Growth	22-07-28	MT
Stifel Nicolaus Adjusts Price Target for CONMED to $110 From $160, Maintains Buy Rating	22-06-23	MT
Needham Lifts CONMED's Price Target to $155 From $150 on In2Bones Acquisition, Reiterates Buy Rating	22-05-05	MT
UBS Adjusts CONMED Price Target to $155 From $165, Maintains Buy Rating	22-01-27	MT
NEEDHAM CUTS CONMED'S PRICE TARGET TO $150 FROM $158 ON MANAGEMENT COMMENTS RE : 'Greater Than Expected' Hit From COVID, Hospital Staffing Issues; Buy Rating Kept	22-01-21	MT